Plinio A. Trinidad-Calderón

Dr. Plinio A. Trinidad-Calderón

Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico
orcid
CMC Expert Leader at Procter & Gamble R&D

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
NSNancy de Los Ángeles Segura-Azuara
Nancy de Los Ángeles Segura-Azuara
CVCarlos Daniel Varela-Chinchilla
Carlos Daniel Varela-Chinchilla
Plinio A. Trinidad-CalderónPlinio A. Trinidad-Calderón
Plinio A. Trinidad-Calderón
Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease, is the most prevalent liver disorder worldwide. Historically, its diagnosis required biopsy, even though the procedure has a variable degree of error. Therefore, new non-invasive strategies are needed. Consequently, this article presents a thorough review of biopsy-free scoring systems proposed for the diagnosis of MAFLD. Similarly, it compares the severity of the disease, ranging from hepatic steatosis (HS) and nonalcoholic steatohepatitis (NASH) to fibrosis, by contrasting the corresponding serum markers, clinical associations, and performance metrics of these biopsy-free scoring systems. In this regard, defining MAFLD in conjunction with non-invasive tests can accurately identify patients with fatty liver at risk of fibrosis and its complications. Nonetheless, several biopsy-free scoring systems have been assessed only in certain cohorts; thus, further validation studies in different populations are required, with adjustment for variables, such as body mass index (BMI), clinical settings, concomitant diseases, and ethnic backgrounds. Hence, comprehensive studies on the effects of age, morbid obesity, and prevalence of MAFLD and advanced fibrosis in the target population are required. Nevertheless, the current clinical practice is urged to incorporate biopsy-free scoring systems that demonstrate adequate performance metrics for the accurate detection of patients with MAFLD and underlying conditions or those with contraindications of biopsy.

9 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Plinio A. Trinidad-CalderónPlinio A. Trinidad-Calderón
Plinio A. Trinidad-Calderón
CVCarlos Daniel Varela-Chinchilla
Carlos Daniel Varela-Chinchilla
SGSilverio García-Lara
Silverio García-Lara
Nowadays, cancer has become the second highest leading cause of death, and it is expected to continue to affect the population in forthcoming years. Additionally, treatment options will become less accessible to the public as cases continue to grow and disease mechanisms expand. Hence, specific candidates with confirmed anticancer effects are required to develop new drugs. Among the novel therapeutic options, proteins are considered a relevant source, given that they have bioactive peptides encrypted within their sequences. These bioactive peptides, which are molecules consisting of 2–50 amino acids, have specific activities when administered, producing anticancer effects. Current databases report the effects of peptides. However, uncertainty is found when their molecular mechanisms are investigated. Furthermore, analyses addressing their interaction networks or their directly implicated mechanisms are needed to elucidate their effects on cancer cells entirely. Therefore, relevant peptides considered as candidates for cancer therapeutics with specific sequences and known anticancer mechanisms were accurately reviewed. Likewise, those features which turn certain peptides into candidates and the mechanisms by which peptides mediate tumor cell death were highlighted. This information will make robust the knowledge of these candidate peptides with recognized mechanisms and enhance their non-toxic capacity in relation to healthy cells and further avoid cell resistance.

1 July 2021 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
JTJorge Alfonso Tavares-Negrete
Jorge Alfonso Tavares-Negrete
AAAlberto Emanuel Aceves-Colin
Alberto Emanuel Aceves-Colin
DRDelia Cristal Rivera-Flores
Delia Cristal Rivera-Flores
GDGladys Guadalupe Díaz-Armas
Gladys Guadalupe Díaz-Armas
AMAnne-Sophie Mertgen
Anne-Sophie Mertgen
GSGrissel Trujillo de Santiago
Grissel Trujillo de Santiago

1 July 2021 in Journal of Cereal Science
Verified
Journal Article
Closed access
Plinio A. Trinidad-CalderónPlinio A. Trinidad-Calderón
Plinio A. Trinidad-Calderón
EAErika Acosta-Cruz
Erika Acosta-Cruz
MRMaría Natalia Rivero-Masante
María Natalia Rivero-Masante
JDJorge L. Díaz-Gómez
Jorge L. Díaz-Gómez
SGSilverio García-Lara
Silverio García-Lara
LLLaura Margarita López-Castillo
Laura Margarita López-Castillo

Verified
Journal Article
Open access
PDF file
CVCarlos Daniel Varela-Chinchilla
Carlos Daniel Varela-Chinchilla
DSDaniela Edith Sánchez-Mejía
Daniela Edith Sánchez-Mejía
Plinio A. Trinidad-CalderónPlinio A. Trinidad-Calderón
Plinio A. Trinidad-Calderón
Congenital heart disease is one of the most common causes of death derived from malformations. Historically, its treatment has depended on timely diagnosis and early pharmacological and surgical interventions. Survival rates for patients with this disease have increased, primarily due to advancements in therapeutic choices, but mortality remains high. Since this disease is a time-sensitive pathology, pharmacological interventions are needed to improve clinical outcomes. Therefore, we analyzed the applications, dosage, and side effects of drugs currently used for treating congenital heart disease. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and potassium-sparing diuretics have shown a mortality benefit in most patients. Other therapies, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostaglandins, and soluble guanylyl cyclase stimulators, have benefited patients with pulmonary artery hypertension. Likewise, the adjunctive symptomatic treatment of these patients has further improved the outcomes, since antiarrhythmics, digoxin, and non-steroidal anti-inflammatory drugs have shown their benefits in these cases. Conclusively, these drugs also carry the risk of troublesome adverse effects, such as electrolyte imbalances and hemodynamic compromise. However, their benefits for survival, symptom improvement, and stabilization outweigh the possible complications from their use. Thus, cases must be assessed individually to accurately identify interventions that would be most beneficial for patients.

9 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Plinio A. Trinidad-CalderónPlinio A. Trinidad-Calderón
Plinio A. Trinidad-Calderón
CVCarlos Daniel Varela-Chinchilla
Carlos Daniel Varela-Chinchilla
SGSilverio García-Lara
Silverio García-Lara
Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future.